Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile

References

• Levine DP. Vancomycin: a history. Clin Infect Dis 2006;42(1):S5-12
   PubMed Web of Science ®Google Scholar
• Nicolaou K, Boddy C, Bräse S, et al. Chemistry, biology, and Medicine of the glycopeptide antibiotics. Angew Chem Int Ed Engl 1999;38(15):2096-152
   PubMed Web of Science ®Google Scholar
• Butler MS, Hansford KA, Blaskovich MAT, et al. Glycopeptide antibiotics: back to the future. J Antibiot 2014;67(9):631-44
   PubMed Web of Science ®Google Scholar
• Murray BE, Arias CA, Nannini EC. Glycopeptides (Vancomycin and Teicoplanin), Streptogramins (Quinupristin-Dalfopristin), Lipopeptides (Daptomycin), and Lipoglycopeptides (Telavancin). In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, douglas, and bennett’s principles and practice of infectious diseases. Elsevier Inc; Philadelphia: 2015. p. 377-400
   Google Scholar
• PubChem Compound Database; CID=14969. National Center for biotechnology information. Available from: http://pubchem.ncbi.nlm.nih.gov/compound/14969 [Last accessed 24 June 2015]
   Google Scholar
• Pfeiffer RR. Structural features of vancomycin. Rev Infect Dis 1981;3:S205-9
   PubMedGoogle Scholar
• Rubinstein E, Keynan Y. Vancomycin revisited - 60 years later. Front Public Health 2014;2:217
   PubMedGoogle Scholar
• Howden BP, Davies JK, Johnson PDR, et al. Reduced vancomycin susceptibility in staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010;23(1):99-139
   PubMed Web of Science ®Google Scholar
• Parenti F, Beretta G, Berti M, et al. Teichomycins, new antibiotics from actinoplanes teichomyceticus Nov. Sp. J Antibiot 1978;31(4):276-83
   PubMed Web of Science ®Google Scholar
• Parenti F. Structure and mechanism of action of teicoplanin. J of Hospital Infection 1986;7:79-83
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010;70(7):859-86
   PubMed Web of Science ®Google Scholar
• Uttley AHC, George RC, Naidoo J, et al. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect 1989;103(01):173-81
   PubMed Web of Science ®Google Scholar
• Gold HS. Vancomycin-resistant enterococci: mechanisms and clinical observations. Clin Infect Dis 2001;33(2):210-19
   PubMed Web of Science ®Google Scholar
• Rice LB. Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones. Mayo Clin Proc 2012;87(2):198-208
   PubMed Web of Science ®Google Scholar
• Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol 2012;10(4):266-78
   PubMed Web of Science ®Google Scholar
• Nikolaidis I, Favini-Stabile S, Dessen A. Resistance to antibiotics targeted to the bacterial cell wall. Protein Sci 2014;23(3):243-59
   PubMed Web of Science ®Google Scholar
• Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;72(2):195-8
   PubMedGoogle Scholar
• Tenover FC, Moellering RC. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007;44(9):1208-15
   PubMed Web of Science ®Google Scholar
• Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348(14):1342-7
   PubMed Web of Science ®Google Scholar
• Gould IM. VRSA-doomsday superbug or damp squib? Lancet Infect Dis 2010;10(12):816-18
   PubMed Web of Science ®Google Scholar
• Melo-Cristino J, Resina C, Manuel V, et al. First case of infection with vancomycin-resistant staphylococcus aureus in Europe. Lancet 2013;382(9888):205
   PubMed Web of Science ®Google Scholar
• Foucault M-L, Courvalin P, Grillot-Courvalin C. Fitness cost of VanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009;53(6):2354-9
   PubMed Web of Science ®Google Scholar
• Antibiotic resistance threats in the United States, 2013. Centers for disease control and prevention. Available from: www.cdc.gov/drugresistance/threat-report-2013/index.html [Last accessed 24 June 2015]
   Google Scholar
• Howden BP. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA). Intern Med J 2005;35(2):S136-40
   PubMed Web of Science ®Google Scholar
• Wootton M, Howe RA, Hillman R, et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001;47(4):399-403
   PubMed Web of Science ®Google Scholar
• Casapao AM, Davis SL, McRoberts JP, et al. Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2014;58(8):4636-41
   PubMed Web of Science ®Google Scholar
• Vandecasteele SJ, De Vriese AS, Tacconelli E. The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. J Antimicrob Chemother 2013;68(4):743-8
   PubMed Web of Science ®Google Scholar
• Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340(7):493-501
   PubMed Web of Science ®Google Scholar
• Charles PGP, Ward PB, Johnson PDR, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004;38(3):448-51
   PubMed Web of Science ®Google Scholar
• Howden BP, Ward PB, Charles PGP, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004;38(4):521-8
   PubMed Web of Science ®Google Scholar
• Howden BP, Johnson PDR, Ward PB, et al. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006;50(9):3039-47
   PubMed Web of Science ®Google Scholar
• Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997–2001. Clin Infect Dis 2003;36(4):429-39
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012;54(6):755-71
   PubMed Web of Science ®Google Scholar
• Mavros MN, Tansarli GS, Vardakas KZ, et al. Impact of vancomycin minimum inhibitory concentration on clinical outcomes of patients with vancomycin-susceptible staphylococcus aureus infections: a meta-analysis and meta-regression. Int J Antimicrob Agents 2012;40(6):496-509
   PubMed Web of Science ®Google Scholar
• Casapao AM, Leonard SN, Davis SL, et al. Clinical outcomes in patients with heterogeneous vancomycin-intermediate staphylococcus aureus (hVISA) bloodstream infection. Antimicrob Agents Chemother 2013;57(9):4252-9
   PubMed Web of Science ®Google Scholar
• Jacob JT, DiazGranados CA. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis. Int J Infect Dis 2013;17(2):e93-e100
   PubMed Web of Science ®Google Scholar
• Cervera C, Castañeda X, de la Maria CG, et al. Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis. Clin Infect Dis 2014;58(12):1668-75
   PubMed Web of Science ®Google Scholar
• Kalil AC, Van Schooneveld TC, Fey PD, Rupp ME. Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis. JAMA 2014;312(15):1552-64
   PubMed Web of Science ®Google Scholar
• Jobson S, Moise PA, Eskandarian R. Retrospective observational study comparing vancomycin versus daptomycin as initial therapy for Staphylococcus aureus infections. Clin Ther 2011;33(10):1391-9
   PubMed Web of Science ®Google Scholar
• Patel N, Pai MP, Rodvold KA, et al. Vancomycin: we can’t get there from here. Clin Infect Dis 2011;52(8):969-74
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Fowler VG. Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis 2013;56(12):1779-88
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52(3):e18-55
   PubMed Web of Science ®Google Scholar
• Rybak MJ. Pharmacodynamics: relation to antimicrobial resistance. Am J Med 2006;119(6A):S37-44
   PubMed Web of Science ®Google Scholar
• Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006;42(1):S35-9
   PubMed Web of Science ®Google Scholar
• Larsson AJ, Walker KJ, Raddatz JK, et al. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother 1996;38(4):589-97
   PubMed Web of Science ®Google Scholar
• Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Am J of Health-System Pharmacy 2008;66(1):82-98
   Google Scholar
• LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004;48(12):4665-72
   PubMed Web of Science ®Google Scholar
• Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003;17(3):479-501
   PubMed Web of Science ®Google Scholar
• Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004;43(13):925-42
   PubMed Web of Science ®Google Scholar
• Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011;52(8):975-81
   PubMed Web of Science ®Google Scholar
• Holmes NE, Turnidge JD, Munckhof WJ, et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2013;57(4):1654-63
   PubMed Web of Science ®Google Scholar
• Lodise TP, Drusano GL, Zasowski E, et al. Vancomycin exposure in patients with methicillin-resistant staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis 2014;59(5):666-75
   PubMed Web of Science ®Google Scholar
• Neely MN, Youn G, Jones B, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother 2014;58(1):309-16
   PubMed Web of Science ®Google Scholar
• Vaudaux P, Huggler E, Bernard L, et al. Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus. Antimicrob Agents Chemother 2010;54(9):3861-70
   PubMed Web of Science ®Google Scholar
• Prakash V, Lewis JS, Jorgensen JH. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother 2008;52(12):4528-8
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Vidaillac C, Sader HS, et al. Evaluation of vancomycin susceptibility testing for methicillin-resistant staphylococcus aureus: comparison of etest and three automated testing methods. J Clin Microbiol 2013;51(7):2077-81
   PubMed Web of Science ®Google Scholar
• Casapao AM, Lodise TP, Davis S, et al. The association between the vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. Antimicrob Agents Chemother 2015;59(6):2978-85
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Trapp S, Gin AS, et al. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of gram-positive infections. Expert Rev Anti Infect Ther 2008;6(1):67-81
   PubMed Web of Science ®Google Scholar
• Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 2007;51(5):1633-42
   PubMed Web of Science ®Google Scholar
• Kim A, Kuti JL, Nicolau DP. Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Expert Opin Investig Drugs 2007;16(5):717-33
   PubMed Web of Science ®Google Scholar
• Durata therapeutics international. Dalvance full prescribing information. 2014
   Google Scholar
• Pankuch GA, Appelbaum PC. Postantibiotic effects of telavancin against 16 gram-positive organisms. Antimicrob Agents Chemother 2009;53(3):1275-7
   PubMed Web of Science ®Google Scholar
• Hegde SS, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria. Antimicrob Agents Chemother 2004;48(8):3043-50
   PubMed Web of Science ®Google Scholar
• Charneski L, Patel PN, Sym D. Telavancin: a novel lipoglycopeptide antibiotic. Annals Pharmacotherapy 2009;43(5):928-38
   PubMed Web of Science ®Google Scholar
• Theravance biopharma. Vibativ full prescribing information. 2014
   Google Scholar
• Wu G, Truong J, Lee S, et al. Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections. Expert Rev Anti Infect Ther 2015;13(4):409-16
   PubMed Web of Science ®Google Scholar
• Guskey MT, Tsuji BT. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacother 2010;30(1):80-94
   PubMed Web of Science ®Google Scholar
• Theravance Biopharma. Orbactiv Full Prescribing Information. 2014
   Google Scholar
• Lode H, Boeckh M, Höffken G, et al. Comparative pharmacokinetics of glycopeptide antibiotics, and the influence of teicoplanin on granulocyte function. Scand J Infect Dis Suppl 1990;72:9-13
   PubMedGoogle Scholar
• Lomaestro BM. Vancomycin dosing and monitoring 2 years after the guidelines. Expert Rev Anti Infect Ther 2011;9(6):657-67
   PubMed Web of Science ®Google Scholar
• Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986;11(4):257-82
   PubMed Web of Science ®Google Scholar
• Quale JM, O’Halloran JJ, DeVincenzo N, et al. Removal of vancomycin by high-flux hemodialysis membranes. Antimicrob Agents Chemother 1992;36(7):1424-6
   PubMed Web of Science ®Google Scholar
• Barth RH, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int 1996;50(3):929-36
   PubMed Web of Science ®Google Scholar
• Vandecasteele SJ, De Vriese AS. Vancomycin dosing in patients on intermittent hemodialysis. Semin Dial 2011;24(1):50-5
   PubMed Web of Science ®Google Scholar
• Grace E. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J Antimicrob Chemother 2012;67(6):1305-10
   PubMed Web of Science ®Google Scholar
• Blot S, Koulenti D, Akova M, et al. Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Crit Care 2014;18(3):R99
   PubMed Web of Science ®Google Scholar
• Bunke CM, Aronoff GR, Brier ME, et al. Vancomycin kinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1983;34(5):631-7
   PubMed Web of Science ®Google Scholar
• Pollard TA, Lampasona V, Akkerman S, et al. Vancomycin redistribution: dosing recommendations following highflux hemodialysis. Kidney Int 1994;45(1):232-7
   PubMed Web of Science ®Google Scholar
• Young JF, Luecke RH, Pearce BA, et al. Human Organ/Tissue Growth Algorithms that Include Obese Individuals and Black/White Population Organ Weight Similarities from Autopsy Data. J Toxicol Environ Health A 2009;72(8):527-40
   PubMed Web of Science ®Google Scholar
• Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 2000;39(3):167-83
   PubMed Web of Science ®Google Scholar
• Harding I, MacGowan AP, White LO, et al. Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother 2000;45(6):835-41
   PubMed Web of Science ®Google Scholar
• Darley ESR, MacGowan AP. The use and therapeutic drug monitoring of teicoplanin in the UK. Clin Microbiol Infect 2004;10(1):62-9
   PubMed Web of Science ®Google Scholar
• Cavaleri M, Riva S, Valagussa A, et al. Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother 2005;55(2):ii31-5
   PubMedGoogle Scholar
• Buckwalter M, Dowell JA. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol 2005;45(11):1279-87
   PubMed Web of Science ®Google Scholar
• Dunbar LM, Tang DM, Manausa RM. A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI). Ther Clin Risk Manag 2008;4(1):235-44
   PubMedGoogle Scholar
• Ambrose PG, Drusano GL, Craig WA. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin Infect Dis 2012;54(3):S220-8
   PubMed Web of Science ®Google Scholar
• Cabellos C, Fernàndez A, Maiques JM, et al. Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 2003;47(6):1907-11
   PubMed Web of Science ®Google Scholar
• Cavalcanti AB, Goncalves AR, Almeida CS, et al. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev 2010;6:CD007022
   PubMed Web of Science ®Google Scholar
• Elyasi S, Khalili H, Dashti-Khavidaki S. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. Eur J Clin Pharmacol 2012;68(9):1243-55
   PubMed Web of Science ®Google Scholar
• Mergenhagen KA, Borton AR. Vancomycin nephrotoxicity: a review. J Pharm Pract 2014;27(6):545-53
   PubMedGoogle Scholar
• van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013;57(2):734-44
   PubMed Web of Science ®Google Scholar
• Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother 2009;53(10):4069-79
   PubMed Web of Science ®Google Scholar
• Myers AL, Gaedigk A, Dai H, et al. Defining risk factors for red man syndrome in children and adults. Ped Infect Dis J 2012;31(5):464-8
   PubMed Web of Science ®Google Scholar
• Black E, Lau TTY, Ensom MHH. Vancomycin-induced neutropenia: is it dose- or duration-related? Ann Pharmacother 2011;45(5):629-38
   PubMed Web of Science ®Google Scholar
• Smith PF, Taylor CT. Vancomycin-induced neutropenia associated with fever: similarities between two immune-mediated drug reactions. Pharmacother 1999;19(2):240-4
   PubMed Web of Science ®Google Scholar
• Patel P, Sandoe J, Baig W. Teicoplanin-induced leucopenia with immediate resolution after administration of G-CSF. BMJ Case Rep 2012
   Google Scholar
• Hsiao SH, Chen HH, Chou CH, et al. Teicoplanin-induced hypersensitivity syndrome with a preceding vancomycin-induced neutropenia: a case report and literature review. J Clin Pharm Ther 2010;35(6):729-32
   PubMed Web of Science ®Google Scholar
• Booth K, Parissis H. Teicoplanin-induced neutropenic sepsis mimicking endocarditis. Asian Cardiovasc Thorac Ann 2012;20(4):460-2
   PubMedGoogle Scholar
• Cadle RM, Mansouri MD, Darouiche RO. Vancomycin-induced elevation of liver enzyme levels. Ann Pharmacother 2006;40(6):1186-9
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang XY, Zeckel M, et al. Risk of Hepatic Events in Patients Treated with Vancomycin in Clinical Studies. Drug Saf 2011;34(1):73-82
   PubMed Web of Science ®Google Scholar
• Ueda T, Takesue Y, Nakajima K, et al. High-dose regimen to achieve novel target trough concentration in teicoplanin. J Infect Chemother 2014;20(1):43-7
   PubMed Web of Science ®Google Scholar
• Benoit L, Gray MH, Sligl WI. Severe tremor due to vancomycin therapy: a case report and literature review. Int J Infect Dis 2012;16(8):e636-7
   PubMed Web of Science ®Google Scholar
• Stille W, Sietzen W, Dieterich HA, et al. Clinical efficacy and safety of teicoplanin. J Antimicrob Chemother 1988;21(Suppl A):69-79
   PubMed Web of Science ®Google Scholar
• Sharif-Yakan A, Arabi M, Musharrafieh UM, et al. Complete heart block in a patient with acute lymphoblastic leukaemia: teicoplanin as a possible cause and review of literature. J Clin Pharm Ther 2013;38(2):156-8
   PubMed Web of Science ®Google Scholar
• Enseleit F, Mueller NJ, Duru F, et al. Teicoplanin-induced complete AV-block in a heart transplant recipient. Infection 2008;36(3):291-2
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin Infect Dis 2008;46(11):1683-93
   PubMed Web of Science ®Google Scholar
• Barriere SL. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. Future Microbiol 2014;9(3):281-9
   PubMed Web of Science ®Google Scholar